Eli Lilly & Co Stock Forecast for 2023 - 2025 - 2030
Updated on 06/04/2023
Eli Lilly & Co Stock Forecast and Price Target
Based on the current earnings figures, this year's price targets for Eli Lilly & Co were recently set by twelve distinguished experts, with an average mark of $400.00. If it reached this goal, it would represent a potential downside of approximately -9.57% from the previous closing price in June, 2023. The high end is $440.00, and the low is $202.00. If you're looking for information on Eli Lilly & Co stock, consider checking out the forecasts for comparable firms such as NYSE:BMY.
-9.57% Downside
Eli Lilly & Co Fair Value Forecast for 2023 - 2025 - 2030
Eli Lilly & Co's Price has seen growth In the last three years, going from $142.85 to $163.89 – a gain of 14.74% In the next year, analysts believe that Fair Value will reach $228.70 – an increase of 39.54%. For the next eight years, the forecast is forFair Value to grow by 192.06%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$156.97 | Buy/Sell | $178.79 | 14.99% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$38.36 | Buy/Sell | $47.96 | 37.25% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$112.52 | Buy/Sell | $99.57 | 4.87% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$65.66 | Buy/Sell | $80.99 | 26.41% |
| REGN Stock Forecast | Regeneron Pharmaceuticals Inc | Outperform |
2
|
$739.95 | Buy/Sell | $796.73 | 5.68% |
Eli Lilly & Co Revenue Forecast for 2023 - 2025 - 2030
Eli Lilly & Co's Revenue has seen growth In the last three years, going from $22.32B to $28.54B – a gain of 27.88% In the next year, analysts believe that Revenue will reach $30.45B – an increase of 6.70%. For the next eight years, the forecast is forRevenue to grow by 67.99%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
13
|
$333.78 | Buy/Sell | $363.29 | -2.33% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$171.88 | Buy/Sell | $209.70 | 19.27% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$41.33 | Buy/Sell | $60.73 | 40.33% |
.jpg)
Eli Lilly & Co Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Dividend per Share for Eli Lilly & Co has grown by 75.19%, going from $2.58 to $4.52. According to 11 analysts, Eli Lilly & Co's Dividend per Share will fall by 7.08% in the next year, reaching $4.20. Over the next eight years, experts anticipate that Dividend per Share growth for Eli Lilly & Co will be 165.27%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$193.67 | Buy/Sell | $244.18 | 29.60% |
| VTRS Stock Forecast | Viatris | Outperform |
8
|
$9.33 | Buy/Sell | $13.70 | 44.69% |
| UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$217.22 | Buy/Sell | $280.69 | 35.81% |
Eli Lilly & Co Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last three years, Eli Lilly & Co's Free Cash Flow has increased by 117377026.78%, going from $3.80B to $4463.50T. 10 analysts predict Eli Lilly & Co's Free Cash Flow will decrease by 100.00% in the next year, reaching $8.00B. By 2030, professionals predict that Eli Lilly & Co's Free Cash Flow will decrease by 100.00%, to $15.12B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CTLT Stock Forecast | Catalent | Outperform |
15
|
$37.72 | Buy/Sell | $83.92 | 93.53% |
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$41.75 | Buy/Sell | $52.42 | 19.76% |
| CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$38.63 | Buy/Sell | $62.67 | 55.32% |
Eli Lilly & Co Net Income Forecast for 2023 - 2025 - 2030
In the last three years, Eli Lilly & Co's Net Income has decreased from $8.32B to $6.24B – a 24.93% drop. In the next year, analysts predict that Net Income will reach $8.82B – an increase of 41.22%. For the next eight years, the forecast is for Net Income to grow by 178.14%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$132.82 | Buy/Sell | $163.67 | 23.48% |
| NEOG Stock Forecast | Neogen | Hold |
16
|
$18.51 | Buy/Sell | $37.00 | 37.76% |
| CORT Stock Forecast | Corcept Therapeutics | Outperform |
16
|
$23.26 | Buy/Sell | $0.00 | 26.83% |
Eli Lilly & Co EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Eli Lilly & Co's EBITDA has grown, increasing from $7.23B to $9.43B – an increase of 30.44%. For next year, the 13 analysts predict EBITDA of $11.82B, which would mean an increase of 25.25%. Over the next eight years, the pros' prediction is EBITDAof $20.45B, which would mean a eight-year growth forecast of 116.79%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$26.56 | Buy/Sell | $73.38 | -28.46% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£165.80 | Buy/Sell | £3.79 | -97.14% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$39.09 | Buy/Sell | $79.67 | 99.54% |
Eli Lilly & Co EBIT Forecast for 2023 - 2025 - 2030
Eli Lilly & Co's EBIT has increased by 36.31% In the last two years, going from $6.00B to $8.18B. In the next year, analysts expect EBIT to reach $10.24B – an increase of 25.18%. For the next eight years, the forecast is for EBIT to grow by 143.31%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$46.70 | Buy/Sell | $41.00 | -5.78% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Hold |
14
|
$11.03 | Buy/Sell | $12.60 | 13.33% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$33.53 | Buy/Sell | $35.50 | 1.40% |
Eli Lilly & Co EPS Price Prediction Forecast for 2023 - 2025 - 2030
Eli Lilly & Co's EPS has seen growth In the last three years, going from $6.04 to $6.93 – a gain of 14.74% In the next year, analysts believe that EPS will reach $9.67 – an increase of 39.54%. For the next eight years, the forecast is forEPS to grow by 192.06%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LGND Stock Forecast | Ligand Pharmaceuticals | Outperform |
14
|
$72.13 | Buy/Sell | $195.43 | 119.74% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$259.94 | Buy/Sell | $170.08 | -32.68% |
| USNA Stock Forecast | USANA Health Sciences | Hold |
14
|
$63.54 | Buy/Sell | $104.00 | -10.29% |
.jpg)